Infectitious Diarrhea - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 82 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Infectitious Diarrhea - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Infectitious Diarrhea - Pipeline Review, H2 2014', provides an overview of the Infectitious Diarrhea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Infectitious Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Infectitious Diarrhea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Infectitious Diarrhea
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Infectitious Diarrhea and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Infectitious Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Infectitious Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Infectitious Diarrhea
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Infectitious Diarrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Infectitious Diarrhea Overview 8
Therapeutics Development 9
Pipeline Products for Infectitious Diarrhea - Overview 9
Pipeline Products for Infectitious Diarrhea - Comparative Analysis 10
Infectitious Diarrhea - Therapeutics under Development by Companies 11
Infectitious Diarrhea - Therapeutics under Investigation by Universities/Institutes 13
Infectitious Diarrhea - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Infectitious Diarrhea - Products under Development by Companies 17
Infectitious Diarrhea - Products under Investigation by Universities/Institutes 18
Infectitious Diarrhea - Companies Involved in Therapeutics Development 19
Actelion Ltd 19
Assembly Biosciences, Inc. 20
Cubist Pharmaceuticals, Inc. 21
Napo Pharmaceuticals, Inc. 22
Paratek Pharmaceuticals, Inc. 23
Pfizer Inc. 24
Prokarium Ltd. 25
Shire Plc 26
Summit Corporation plc 27
Infectitious Diarrhea - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
AKT-10081 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
cadazolid - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
clostridium difficile vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
crofelemer DR - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Drugs for CDAD - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
fidaxomicin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
infectious diarrhea vaccine [serotype H11] (H10407 and E24377A) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Peptide for Enterocolitis and Infectious Diarrhea - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
PF-06425090 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PZ-7475 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
RBX-2660 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules for Diarrhea - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecules for Infectious Diarrhea - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
SMT-19969 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
surotomycin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Tetracycline Derivatives for CDAD - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Vaccine for Campylobacter Caused Diarrhea - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
VP-20621 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Infectitious Diarrhea - Recent Pipeline Updates 62
Infectitious Diarrhea - Dormant Projects 77
Infectitious Diarrhea - Product Development Milestones 78
Featured News & Press Releases 78
Feb 25, 2014: Salix Wins Napo Pharmaceuticals Litigation 78
Jan 14, 2014: Fulyzaq 125 mg Delayed-Release Tablets Significantly Improves Noninfectious Diarrhea in Adult Patients Living with HIV on ART Therapy 78
Dec 21, 2012: Actelion's Cadazolid To Move Into Phase III Clinical Development In Patients With Clostridium Difficile Associated Diarrhea 79
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-315 At ICAAC 2012 80
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 82
Disclaimer 82

List of Tables
Number of Products under Development for Infectitious Diarrhea, H2 2014 9
Number of Products under Development for Infectitious Diarrhea - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Infectitious Diarrhea - Pipeline by Actelion Ltd, H2 2014 19
Infectitious Diarrhea - Pipeline by Assembly Biosciences, Inc., H2 2014 20
Infectitious Diarrhea - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 21
Infectitious Diarrhea - Pipeline by Napo Pharmaceuticals, Inc., H2 2014 22
Infectitious Diarrhea - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 23
Infectitious Diarrhea - Pipeline by Pfizer Inc., H2 2014 24
Infectitious Diarrhea - Pipeline by Prokarium Ltd., H2 2014 25
Infectitious Diarrhea - Pipeline by Shire Plc, H2 2014 26
Infectitious Diarrhea - Pipeline by Summit Corporation plc, H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 36
Infectitious Diarrhea Therapeutics - Recent Pipeline Updates, H2 2014 62
Infectitious Diarrhea - Dormant Projects, H2 2014 77